SG11201909595VA - Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil - Google Patents

Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Info

Publication number
SG11201909595VA
SG11201909595VA SG11201909595VA SG11201909595VA SG 11201909595V A SG11201909595V A SG 11201909595VA SG 11201909595V A SG11201909595V A SG 11201909595VA SG 11201909595V A SG11201909595V A SG 11201909595VA
Authority
SG
Singapore
Prior art keywords
donepezil
therapeutic agent
agent combining
dementia therapeutic
pyrazoloquinoline derivative
Prior art date
Application number
Inventor
Mai MIYAMOTO
Sadaharu Kotani
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201909595VA publication Critical patent/SG11201909595VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)--(2-methoxy-3,5-dirnethylpyndin-4-y1)-1-(te ahydrofuran-3-y1)-1H-pyrazolo[4,3-c]qui 5 noline-4(51-1)-one represented by formula (I): O or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): 0 0 0 or a pharmaceutically acceptable salt thereof 20
SG11201909595V 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil SG11201909595VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513692P 2017-06-01 2017-06-01
PCT/JP2018/020638 WO2018221545A1 (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Publications (1)

Publication Number Publication Date
SG11201909595VA true SG11201909595VA (en) 2019-11-28

Family

ID=64455958

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202113198TA SG10202113198TA (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
SG11201909595V SG11201909595VA (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202113198TA SG10202113198TA (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Country Status (12)

Country Link
US (1) US11833146B2 (en)
EP (1) EP3632439B1 (en)
JP (2) JP7079777B2 (en)
KR (1) KR102627787B1 (en)
CN (1) CN110603040B (en)
AU (1) AU2018276565A1 (en)
BR (1) BR112019023569A2 (en)
CA (1) CA3060030A1 (en)
IL (1) IL270395B (en)
RU (1) RU2019135834A (en)
SG (2) SG10202113198TA (en)
WO (1) WO2018221545A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019023552A2 (en) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. THERAPEUTIC AGENT FOR DEMENTIA WITH LEWY BODIES CONTAINING PIRAZOLOQUINOLINE DERIVATIVE
KR102627790B1 (en) 2017-06-01 2024-01-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Dementia treatment using a combination of pyrazoloquinoline derivatives and memantine
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
KR102271305B1 (en) 2020-05-21 2021-06-30 주식회사 아리바이오 Composition for preventing and treating dementia
KR102272907B1 (en) 2020-11-05 2021-07-05 주식회사 아리바이오 Composition for preventing and treating dementia
KR102272910B1 (en) 2021-01-28 2021-07-06 주식회사 아리바이오 Composition for prevention and treating dementia with diabetes
KR20220140960A (en) 2021-04-12 2022-10-19 주식회사 아리바이오 Composition for prevention and treating dementia with diabetes
KR102311224B1 (en) * 2021-04-23 2021-10-13 주식회사 아리바이오 Composition for prevention and treating dementia through the combination of PDE5 inhibitors and glucocorticoid receptor antagonists
KR20220146095A (en) 2021-04-23 2022-11-01 주식회사 아리바이오 Composition for prevention and treating dementia through the combination of PDE5 inhibitors and glucocorticoid receptor antagonists
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05132484A (en) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc Pyrazoloquinoline and pyrazolonaphthylidene derivative
RU2145606C1 (en) 1994-05-24 2000-02-20 Ф.Хоффманн-Ля Рош Аг Tricyclic dicarbonyl derivatives and drug based on said
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
AU5716898A (en) * 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
HN2002000317A (en) 2001-11-02 2003-05-21 Pfizer PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
AU2003250539A1 (en) 2002-08-07 2004-02-25 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
DE10238722A1 (en) 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
DE102004004142A1 (en) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
RU2426734C2 (en) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Pyrazolopyridines and analogues thereof
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (en) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd New pyrazoloquinolone derivative
US8193356B2 (en) 2005-09-15 2012-06-05 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
CA2672591A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Treating agent of uropathy
ES2566774T3 (en) 2006-12-13 2016-04-15 Aska Pharmaceutical Co., Ltd. Quinoxaline derivative
NZ580904A (en) 2007-05-11 2012-02-24 Pfizer Amino-heterocyclic compounds for inhibiting pde9
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
TWI404721B (en) * 2009-01-26 2013-08-11 Pfizer Amino-heterocyclic compounds
BRPI1009287A2 (en) 2009-03-05 2019-09-24 Astellas Pharma Inc quinoxaline compound
JP5542196B2 (en) 2009-03-31 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 1-Heterocyclic-1,5-dihydro-pyrazolo [3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
PE20130602A1 (en) 2010-08-12 2013-05-25 Boehringer Ingelheim Int 6-CYCLOALKYL-1,5-DIHYDRO-PYRAZOLE (3,4-D) PYRIMIDIN-4-ONAS DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS
RS54834B1 (en) 2010-09-07 2016-10-31 Astellas Pharma Inc Pyrazoloquinoline compounds
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) * 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
JP2013051639A (en) 2011-08-31 2013-03-14 Kyocera Document Solutions Inc Image formation means
PL2573073T3 (en) 2011-09-26 2015-04-30 Sanofi Sa Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
JP6042060B2 (en) 2011-09-26 2016-12-14 サノフイ Pyrazoloquinolinone derivatives, their preparation and therapeutic use
ME02394B (en) 2011-10-07 2016-09-20 Eisai R&D Man Co Ltd Pyrazoloquinoline derivative as pde9 inhibitors
JP5666755B1 (en) 2013-04-05 2015-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Salts and crystals of pyrazoloquinoline derivatives
KR102627790B1 (en) 2017-06-01 2024-01-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Dementia treatment using a combination of pyrazoloquinoline derivatives and memantine
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
BR112019023552A2 (en) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. THERAPEUTIC AGENT FOR DEMENTIA WITH LEWY BODIES CONTAINING PIRAZOLOQUINOLINE DERIVATIVE
CN108563565B (en) 2018-04-08 2021-12-17 中国人民解放军海军工程大学 Method for establishing reliability quantitative analysis model of flight landing guidance system

Also Published As

Publication number Publication date
IL270395A (en) 2020-02-27
EP3632439A1 (en) 2020-04-08
US20200129501A1 (en) 2020-04-30
CN110603040B (en) 2023-02-28
BR112019023569A2 (en) 2020-06-02
WO2018221545A1 (en) 2018-12-06
JP7288999B2 (en) 2023-06-08
US11833146B2 (en) 2023-12-05
JPWO2018221545A1 (en) 2020-04-02
SG10202113198TA (en) 2021-12-30
IL270395B (en) 2022-08-01
RU2019135834A (en) 2021-07-13
KR20200010224A (en) 2020-01-30
JP2022110143A (en) 2022-07-28
EP3632439B1 (en) 2024-03-27
CN110603040A (en) 2019-12-20
RU2019135834A3 (en) 2021-10-15
CA3060030A1 (en) 2018-12-06
EP3632439A4 (en) 2021-02-17
JP7079777B2 (en) 2022-06-02
AU2018276565A1 (en) 2019-11-07
KR102627787B1 (en) 2024-01-23

Similar Documents

Publication Publication Date Title
SG11201909595VA (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
SG11201909590XA (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
NZ766835A (en) Pharmaceutical compounds
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
SA519401544B1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as rearranged during transfection kinase inhibitors
MX2022000244A (en) PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF.
MX2018003215A (en) Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors.
MX2018013529A (en) SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS.
MX2022003102A (en) Brd9 bifunctional degraders and their methods of use.
MY155255A (en) Spiro-oxindole compounds and their use as therapeutic agents
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
PH12017500479B1 (en) Liquid inhalation formulation comprising rpl554
MX2018012208A (en) Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders.
MX2019013397A (en) Lewy body disease therapeutic agent containing pyrazoloquinoline derivative.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2019006612A (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
MX2020013785A (en) Pyridopyrimidine derivative, preparation method therefor and medical use thereof.
MX2019010756A (en) Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors.
NZ761680A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
NZ734635A (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
ECSP19084722A (en) 5,6-FUSED BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
MX2018011592A (en) Compound having mutant idh inhibitory activity, preparation method and use thereof.
NZ747797A (en) Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist